DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0221257 A1 Campbell Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0221257 A1 Campbell Et Al US 2010O221257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221257 A1 Campbell et al. (43) Pub. Date: Sep. 2, 2010 (54) BINDING MEMBERS-513 Publication Classification (75) Inventors: Jamie Iain Campbell, (51) Int. Cl. Cambridgeshire (GB); Duncan A 6LX 39/395 (2006.01) James Cochrane, Cambridgeshire C07K 6/00 (2006.01) (GB); Donna Kirsty Finch, CI2N 5/3 (2006.01) Cambridgeshire (GB); Maria A6IP 9/02 (2006.01) Anastasia Teresa Groves, A6IP 9/10 (2006.01) Cambridgeshire (GB); David A6IP II/00 (2006.01) Christopher Lowe, A6IP 25/28 (2006.01) A6IP 9/10 (2006.01) Cambridgeshire (GB); Simon A6IP3/10 (2006.01) Charles Cruwys, Leicestershire A6IP35/00 (2006.01) (GB) A6IP3 L/18 (2006.01) Correspondence Address: CI2N I/00 (2006.01) Medimmune, Limited CI2P 2L/00 (2006.01) One Medimmune Way (52) U.S. Cl. ................ 424/143.1; 530/389.1536/23.53; Gaithersburg, MD 20878 (US) 424/172.1; 530/388.22; 435/243; 435/69.6 (73) Assignee: MEDIMMUNE LIMITED, (57) ABSTRACT CAMBRIDGESHIRE (GB) This invention relates to binding members, especially anti body molecules, specific for interleukin 1 receptor 1 (IL (21) Appl. No.: 12/612,781 1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to (22) Filed: Nov. 5, 2009 IL-1R1 and binds Il-1R1 with a K, of 10 pM or less when measured by KinexatM. The binding members are useful for, Related U.S. Application Data interalia, treatment of disorders mediated by IL-1R1 includ (60) Provisional application No. 61/112,381, filed on Nov. ing rheumatoid arthritis, athma and chronic obstructive pull 7, 2008. monary disease (COPD). Patent Application Publication Sep. 2, 2010 Sheet 1 of 14 US 2010/0221257 A1 Figure 1 Cynomolgus Monkey IL-1R1 extracellular domain cDNA ATGAAAGTGTTACTCCGACTTATTTGTTTCATTGCTCTACTGATTTCTTTTCTGGAGG CTGATAAATGCAATGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAA ATTGATGTTCGTCCCTGTCCTCTTAACCCAAATGAATACAAAGGCACTATAACATGG TATAAAAATGACAGCAAGACACCTATATCTACAGAACAAGCCTCCAGGATTCATCA GCACAAAAAGAAACTTTGGTTTGTTCCTGCTAAGGTAGAAGATTCAGGACATTACTA CTGTGTGGTAAGAAATTCATCTTACTGCCTCAGAATTAAAATAACTGCAAAATTTGT GGAGAATGAGCCTAACTTGTGTTATAATGCAGAAGCCATATTTAAGCAGAGACTAC CCGTTGCAGGAGATGGAGGACTTGTGTGCCCTTATATGGAGTTTTTTAAAGACGAAA ATAATGAGTTACCTAAATTACTGTGGTATAAGGATTGCAAACCTCTACTTCTTGACA ATATAAACTTTAGTGGAGTCAA AGATAGGCTCATCGTGATGAATGTGGCTGAAAAG CATAGAGGGAACTATACTTGTCATGCATCCTACACATACTTGGGCAAGCAATATCCT ATTACCCGGGTAATAGAATTTATTACTCTAGAGGAAAACAAACCCACAAGGCCTGT GATTGTGAGCCCAGCTAATGAGACAATAGAAGTAGACTTGGGATCCCAGATACAAT TGATCTGTAATGTCACTGGCCAGTTGAGTGATACTGCCTACTGGAAGTGGAATGGGT CCTTCATTGATGAACATGACCCAGTGCTAGGGGAAG ACTATTACAGTGTGGAAAAT CCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCAGAAACTGA AAGTAGATTTTATAAACATCCATTTACCTGTTTAGCCAGGAATACACATGGTATGGA TGCAGCATATGTCCAGTTAATATATCCAGTCACTAAATTCCAGAAG Patent Application Publication Sep. 2, 2010 Sheet 2 of 14 US 2010/0221257 A1 Figure 2 Cynomolgus Monkey IL-1R1 extracellular domain amino acid sequence MKVLLRLICFIALLISFLEADKCNEREEKIILVSSANEIDVRPCPLNPNEYKGTITWYKNDS KTPISTEQASRIHQHKKKLWFVPAKVEDSGHYYCVVRNSSYCLRIKITAKFVENEPNLCY NAEAIFKQRLPVAGDGGLVCPYMEFFKDENNELPKLLWYKDCKPLLLDNINFSGVKDR LIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETIEVDLG SQIQLICNVTGQLSDTAYWKWNGSFIDEDDPVLGEDYYSVENPANKRRSTLITVLNISET ESRFYKHPFTCLARNTHGMDAAYVQLIYPVTKFQK Patent Application Publication Sep. 2, 2010 Sheet 3 of 14 US 2010/0221257 A1 Figure 3 Human IL1R1 Fc cDNA nucleotide ATGAAAGTGTTACTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTGGAGG CTGATAAATGCAAGGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAA ATTGATGTTCGTCCCTGTCCTCTTAACCCAAATGAACACAAAGGCACTATAACTTGG TATAAAGATGACAGCAAGACACCTGTATCTACAGAACAAGCCTCCAGGATTCATCA ACACAAAGAGAAACTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTA TTGCGTGGTAAGAAATTCATCTTACTGCCTCAGAATTAAAATAAGTGCAAAATTTGT GGAGAATGAGCCTAACTTATGTTATAATGCACAAGCCATATTTAAGCAGAAACTAC CCGTTGCAGGAGACGGAGGACTTGTGTGCCCTTATATGGAGTTTTTTAAAAATGAAA ATAATGAGTTACCTA AATTACAGTGGTATAAGGATTGCAA ACCTCTACTTCTTGACA ATATACACTTTAGTGGAGTCAAAGATAGGCTCATCGTGATGAATGTGGCTGAAAAG CATAGAGGGAACTATACTTGTCATGCATCCTACACATACTTGGGCAAGCAATATCCT ATTACCCGGGTAATAGAATTTATTACTCTAGAGGAAAACAAACCCACAAGGCCTGT GATTGTGAGCCCAGCTAATGAGACAATGGAAGTAGACTTGGGATCCCAGATACAAT TGATCTGTAATGTCACCGGCCAGTTGAGTGACATTGCTTACTGGAAGTGGAATGGGT CAGTAATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGTGTGGAAAAT CCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCGGAAATTGA AAGTAGATTTTATAAACATCCATTTACCTGTTTTGCCAAGAATACACATGGTATAGA TGCAGCATATATCCAGTTAATATATCCAGTCACTAATTTCCAGAAGAAGGGTGGGCG CGCCGACCCAGCTTTCTTGTACAAAGTGGTGGGGGCCGCCCCCAAATCTTGTGACAA AACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTT CCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCAC ATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCA ACTGGTACG TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGG CAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA CCATCTCCAAAGCCAAAGGGCAGCCCCGAGA ACCACAGGTGTACACCCTGCCCCCA TCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCA AAGGCTT CTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACT ACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGC TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATG CATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA CATCATCATCACCACCATTAA Patent Application Publication Sep. 2, 2010 Sheet 5 of 14 US 2010/0221257 A1 Figure S Cynomolgus Monkey ILIRIFc cDNA nucleotide ATGAAAGTGTTACTCCGACTTATTTGTTTCATTGCTCTACTGATTTCTTTTCTGGAGG CTGATAAATGCAATGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAA ATTGATGTTCGTCCCTGTCCTCTTAACCCAAATGAATACAAAGGCACTATAACATGG TATAAAAATGACAGCAAGACACCTATATCTACAGAACAAGCCTCCAGGATTCATCA GCACAAAAAGAAACTTTGGTTTGTTCCTGCTAAGGTAGAAGATTCAGGACATTACTA CTGTGTGGTAAGAAATTCATCTTACTGCCTCAGAATTAAAATAACTGCAAAATTTGT GGAGAATGAGCCTAACTTGTGTTATAATGCAGAAGCCATATTTAAGCAGAGACTAC CCGTTGCAGGAGATGGAGGACTTGTGTGCCCTTATATGGAGTTTTTTAAAGACGAAA ATAATGAGTTACCTAAATTACTGTGGTATAAGGATTGCAAACCTCTACTTCTTGACA ATATAAACTTTAGTGGAGTCAA AGATAGGCTCATCGTGATGAATGTGGCTGAAAAG CATAGAGGGAACTATACTTGTCATGCATCCTACACATACTTGGGCAAGCAATATCCT ATTACCCGGGTAATAGAATTTATTACTCTAGAGGAAAACAA ACCCACAAGGCCTGT GATTGTGAGCCCAGCTAATGAGACAATAGAAGTAGACTTGGGATCCCAGATACAAT TGATCTGTAATGTCACTGGCCAGTTGAGTGATACTGCCTACTGGAAGTGGAATGGGT CCTTCATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGTGTGGAAAAT CCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCAGAAACTGA AAGTAGATTTTATAAACATCCATTTACCTGTTTAGCCAGGAATACACATGGTATGGA TGCAGCATATGTCCAGTTAATATATCCAGTCACTAAATTCCAGAAGAAGGGTGGGC GCGCCGACCCAGCTTTCTTGTACAAAGTGGTGGGGGCCGCCCCCAAATCTTGTGACA AAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCT TCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCA CATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA ACAGCACGTACCGTGTGGTCAGCCTCCTCACCGTCCTGCACCAGGACTGGCTGAATG GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAA ACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCC ATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAA AGGCT TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAG CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT GCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAA ACATCATCATCACCACCATTAA Patent Application Publication Sep. 2, 2010 Sheet 7 of 14 US 2010/0221257 A1 Figure 7 Human IL-1R1 extracellular sequence MKVLLRLICFALLISSLEADKCKEREEKI ILVSSANEIDVRPCPLNPNEHKGTITWYKDDS KTPVSTEQASRIHQHKEK LWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGG LVCPYMEFFKNENNELPKLQW YKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEE NKPTRPVIVSPANETMEVDL GSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEI ESRFYKHPFTCFAKNTHG DAAYIQLIYPVTNFQK Patent Application Publication Sep. 2, 2010 Sheet 8 of 14 US 2010/0221257 A1 Figure 8 Human IL-1R1 cDNA sequence CACCATGAAAGTGTTACTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTG GAGGCTGATAAATGCAAGGAAC GTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGATGTTCGTCCCTGTC CTCTTA ACCCAAATGAACACAAA GGCACTATAACTTGGTATAAAGATGACAGCAAGACACCTGTATCTACAGAACAAGC CTCCAGGATTCATCA ACACAAAGA GAAACTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTATTGCGTGGT AAGAAATTCATCTTACTGCCTCA GAATTAAAATAAGTGCAAAATTTGTGGAGAATGAGCCTAACTTATGTTATAATGCAC AAGCCATATTTAAGCAGAAACTA CCCGTTGCAGGAGACGGAGGACTTGTGTGCCCTTATATGGAGTTTTTTAAAAATGAA AATAATGAGTTACCTAAATTACA GTGGTATAAGGATTGCAAACCTCTACTTCTTGACAATATACACTTTAGTGGAGTCAA AGATAGGCTCATCGTGATGAATG TGGCTGAAAAGCATAGAGGGAACTATACTTGTCATGCATCCTACACATACTTGGGCA AGCAATATCCTATTACCCGGGTA ATAGAATTTATTACTCTAGAGGAAAACAAACCCACAAGGCCTGTGATTGTGAGCCC AGCTAATGAGACAATGGAAGTAGA CTTGGGATCCCAGATACAATTGATCTGTAATGTCACCGGCCAGTTGAGTGACATTGC TTACTGGAAGTGGAATGGGTCAG TAATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGTGTGGAAAATCCT GCAAACAAAAGAAGGAGTACCCTC ATCACAGTGCTTAATATATCGGAAATTGAAAGTAGATTTTATAAACATCCATTTACC TGTTTTGCCAAGAATACACATGG TATAGATGCAGCATATATCCAGTTAATATATCCAGTCACTAATTTCCAGAAG Patent Application Publication Sep. 2, 2010 Sheet 9 of 14 US 2010/0221257 A1 Figure 9 Cyno IL-1R1 Extracellular sequence (residues 1 to 337) MKVLLRLICFIALLISFLEADKCNEREEKIILVSSANEIDVRPCPLNPNEYKGTITWYKNDS KTPISTEQASRI HQHKKK LWFVPAKVEDSGHYYCVVRNSSYCLRIKITAKFVENEPNLCYNAEAIFKQRLPVAGDGG LVCPYMEFFKDENNELPKLLW YKDCKPLLLDNINFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEE NKPTRPVVSPANETIEVDL GSQIQLICNVTGQLSDTAYWKWNGSFIDEDDPVLGEDYYSVENPANKRRSTLITVLNISE TESRFYKHPFTCLARNTHGM DAAYVOLIYPVTKFQK Patent Application Publication Sep. 2, 2010 Sheet 10 of 14 US 2010/0221257 A1 Figure 10 Cyno cDNA extracellular IL-1R1 sequence CACCATGAAAGTGTTACTCCGACTTATTTGTTTCATTGCTCTACTGATTTCTTTTCTG GAGGCTGATAAATGCAATGAAC GTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGATGTTCGTCCCTGTC CTCTTAACCCAAATGAATACAAA GGCACTATA ACATGGTATAAAAATGACAGCAAGACACCTATATCTACAGAACAAGC
Load more

Recommended publications
  • Ep 2492268 A1
    (19) & (11) EP 2 492 268 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.08.2012 Bulletin 2012/35 C07D 407/10 (2006.01) A61K 31/405 (2006.01) (21) Application number: 12168896.4 (22) Date of filing: 20.07.2007 (84) Designated Contracting States: • Wynne, Graham Michael AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Abingdon, Oxfordshire OX14 4RY (GB) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Dorgan, Colin Richard SI SK TR Abingdon, Oxfordshire OX14 4RY (GB) Designated Extension States: • Johnson, Peter David AL BA HR MK RS Abingdon, oxfordshire OX14 4RY (GB) (30) Priority: 22.07.2006 GB 0614608 (74) Representative: Hollywood, Jane Constance 04.12.2006 GB 0624176 Kilburn & Strode LLP 20 Red Lion Street (62) Document number(s) of the earlier application(s) in London WC1R 4PJ (GB) accordance with Art. 76 EPC: 07766323.5 / 2 046 740 Remarks: This application was filed on 22-04-2012 as a (71) Applicant: Oxagen Limited divisional application to the application mentioned Oxfordshire OX14 4RY (GB) under INID code 62. (72) Inventors: • Armer, Richard Edward Abingdon, Oxfordshire OX14 4RY (GB) (54) Compounds having CRTH2 antagonist activity (57) Compounds of general formula (1) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically ac- ceptable salts, hydrates, solvates, complexes or prod- rugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, aller- gic rhinitis and atopic dermatitis. EP 2 492 268 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 492 268 A1 Description [0001] The present invention relates to compounds which are useful as pharmaceuticals, to methods for preparing these compounds, compositions containing them and their use in the treatment and prevention of allergic diseases such 5 as asthma, allergic rhinitis and atopic dermatitis and other inflammatory diseases mediated by prostaglandin D 2 (PGD2) or other agonists acting at the CRTH2 receptor on cells including eosinophils, basophils and Th2 lymphocytes.
    [Show full text]
  • Aryloxime Aryloximes Aryloxymes
    (19) TZZ___¥_T (11) EP 1 511 737 B1 (12) EUROPÄISCHE PATENTSCHRIFT (45) Veröffentlichungstag und Bekanntmachung des (51) Int Cl.: Hinweises auf die Patenterteilung: C07D 237/04 (2006.01) C07D 401/12 (2006.01) 17.02.2010 Patentblatt 2010/07 A61K 31/50 (2006.01) A61P 37/00 (2006.01) (21) Anmeldenummer: 03732395.3 (86) Internationale Anmeldenummer: PCT/EP2003/005173 (22) Anmeldetag: 16.05.2003 (87) Internationale Veröffentlichungsnummer: WO 2003/104205 (18.12.2003 Gazette 2003/51) (54) ARYLOXIME ARYLOXIMES ARYLOXYMES (84) Benannte Vertragsstaaten: • BEIER, Norbert AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 64354 Reinheim (DE) HU IE IT LI LU MC NL PT RO SE SI SK TR • SCHELLING, Pierre Benannte Erstreckungsstaaten: 64367 Mühltal (DE) LT LV • WOLF, Michael 64297 Darmstadt (DE) (30) Priorität: 10.06.2002 DE 10225574 (56) Entgegenhaltungen: (43) Veröffentlichungstag der Anmeldung: WO-A-98/06704 WO-A-99/65880 09.03.2005 Patentblatt 2005/10 Bemerkungen: (73) Patentinhaber: Merck Patent GmbH Die Akte enthält technische Angaben, die nach dem 64293 Darmstadt (DE) Eingang der Anmeldung eingereicht wurden und die nicht in dieser Patentschrift enthalten sind. (72) Erfinder: • EGGENWEILER, Hans-Michael 64291 Darmstadt (DE) Anmerkung: Innerhalb von neun Monaten nach Bekanntmachung des Hinweises auf die Erteilung des europäischen Patents im Europäischen Patentblatt kann jedermann nach Maßgabe der Ausführungsordnung beim Europäischen Patentamt gegen dieses Patent Einspruch einlegen. Der Einspruch gilt erst als eingelegt, wenn die Einspruchsgebühr entrichtet
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Drugs Used in the Treatment of Respiratory System Diseases Antiasthmatic Drugs
    Drugs used in the treatment of respiratory system diseases Antiasthmatic drugs 1 Asthma Asthma is a chronic inflammatory disorder which is accompanied by bronchi contraction, increased release of sticky mucus, edema and exfoliation of the epithelium of the bronchi. The most common form of asthma is allergic asthma (atopic or extrinsic asthma). It is associated with environmental allergens, such as plant pollens, house dust mites, domestic pet dander, molds, and foods. The less common form, intrinsic asthma, has no known allergic cause and usually occurs in adults older than 35 years. Intrinsic asthma may result from an autonomic dysfunction characterized by excess cholinergic and/or tachykinin activity, but this hypothesis has never been proven. 2 3 Antiasthmatic drugs Astma symptoms are caused by bronchoconstruction and inflammation, and approaches to treatment are directed at both these physiological problems. Therefore, drugs that affect adrenergic/cholinergic bronchial smooth muscle tone and drugs that inhibit the inflammatory process are used to treat and control asthma symptoms. In the normal lung, bronchiole smooth muscle tone results from the balance between the bronchoconstrictive effects of the cholinergic system and the bronchodilating effects of the adrenergic system on the smooth muscles of the bronchioles. Pharmacological treatment of asthmatic bronchoconstriction consists of either increasing adrenergic tone with an adrenergic agonist (or phosphodiesterase inhibitors) or inhibiting cholinergic tone with anticholinergic agent. 4 The inflammatory effects seen in asthma result from the release of physiologically active chemicals from a variety of inflammatory cells. Pharmacological treatment, therefore, uses: . anti-inflammatory drugs (corticosteroids), . mast cell stabilizers, . leukotriene modifiers, and . IgE monoclonal antibodies.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • WO 2009/114650 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 17 September 2009 (17.09.2009) WO 2009/114650 Al (51) International Patent Classification: (US). GOSWAMY, Amit [US/US]; 130 Knowles Drive, A61K 31/10 (2006.01) A61K 45/06 (2006.01) Suite A, Los Gatos, CA 95032 (US). A61K 31/195 (2006.01) A61P 29/00 (2006.01) (74) Agents: NOLAN, James S. @ et al.; Mintz Levin Cohn (21) International Application Number: Ferris Glovsky And Popeo, P.C , One Financial Center, PCT/US2009/036867 Boston, MA 021 11 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 11 March 2009 ( 11.03.2009) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (26) Publication Language: English EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/035,706 11 March 2008 ( 11.03.2008) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (71) Applicant (for all designated States except US): CHAK- NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SHU RESEARCH, INC. [US/US]; 130 Knowles Drive, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, Suite A, Los Gatos, CA 95032 (US).
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,250,518 B2 Magee Et Al
    US007250518B2 (12) United States Patent (10) Patent No.: US 7,250,518 B2 Magee et al. (45) Date of Patent: Jul. 31, 2007 (54) NICOTINAMIDE ACIDS, AMIDES, AND WO WO O157O25 8, 2001 THER MIMETCS ACTIVE AS INHIBITORS WO WO O157.036 8, 2001 OF PDE4 ISOZYMES (75) Inventors: Thomas V. Magee, Mystic, CT (US); OTHER PUBLICATIONS Anthony Marfat, Mystic, CT (US); Trophy, Theodore J. et al., “Phosphodiesterase IV Inhibitors as Robert J. Chambers, Mystic, CT (US) Therapy for Eosinophil-induced Lung Injury in Asthma, Environ mental Health Perspectives, vol. 102 Suppl. 10, Dec. 1994, pp. (73) Assignee: Pfizer Inc., New York, NY (US) 79-84. Duplantier, Allen J., et al., "Biarylcarboxylic Acids and -amides: (*) Notice: Subject to any disclaimer, the term of this Inhibition of PhosphodiesteraseType IV versus HIRolipram Bind patent is extended or adjusted under 35 ing Activity and Their Relationship to Emetic Behavior in the U.S.C. 154(b) by 340 days. Ferret, Journal of Medicinal Chemistry.” 1996, vol. 39, No. 1, pp. 120-125. (21) Appl. No.: 10/781,062 Schneider, Herbert H. et al., “Dicriminative Stimulus Properties of the Stereoisomers of the Phosphodiesterase Inhibitor Rolipram.” Pharmacology Biochemistry and Behavior, vol. 50, No. 2, 1995, pp. (22) Filed: Feb. 17, 2004 211-217. (65) Prior Publication Data Banner, Katherine H., et. al., “Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell US 2004/0171798 A1 Sep. 2, 2004 influx in sensitized guinea-pigs, British Journal of Pharmacology, 114, 1995, pp. 93-98. Related U.S. Application Data Barnette, Mary S., et. al., “The Ability of Phosphodiesterase IV Inhibitors to Suppress Superoxide Production in Guinea Pig (63) Continuation of application No.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]